

Supporting information

TABLE S1: Sample size in clinical studies from vildagliptin clinical trial programme, monotherapy and vildagliptin plus metformin.

Study	Vildagliptin 50 mg qd/bid	Vildagliptin 50 mg + metformin
	(n=2523)	(n=2752)
1	5	-
2	200	-
3	135	-
4	436	-
5	469	-
6	58	-
7	393	-
8	431	-
9	6	-
10	14	-
11	132	-
12	244	421
13	-	145
14	-	112
15	-	1363
16	-	449
17	-	262

bid, twice daily; qd, once daily

Supplementary references

1. S. Ristic, S. Byiers, J. Foley, and D. Holmes, "Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response," *Diabetes Obesity and Metabolism*, vol. 7, no. 6, pp. 692–698, 2005.
2. S. Dejager, S. Razac, J. E. Foley, and A. Schweizer, "Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study," *Hormone and Metabolic Research*, vol. 39, no. 3, pp. 218–223, 2007.
3. W. A. Scherbaum, A. Schweizer, A. Mari et al., "Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*," *Diabetes Obesity and Metabolism*, vol. 10, no. 8, pp. 675–682, 2008.
4. A. Schweizer, A. Couturier, J. E. Foley, and S. Dejager, "Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes," *Diabetic Medicine*, vol. 24, no. 9, pp. 955–961, 2007.
5. J. E. Foley and S. Sreenan, "Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes," *Hormone and Metabolic Research*, vol. 41, no. 12, pp. 905–909, 2009.
6. H. Krum, V. Lukashevich, G. B. Bolli, P. Kozlovski, W. Kothny, and P. Ponikowski, "No significant difference in risk of heart failure hospitalization with vildagliptin in diabetic patients with systolic chronic heart failure: VIVID study," *Diabetes*, vol. 63, Supplement 1, pp. A743, 2014.

7. C. Pan, W. Yang, J. P. Barona et al., "Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial," *Diabetic Medicine*, vol. 25, no. 4, pp. 435–441, 2008.
8. J. Rosenstock, M. A. Baron, S. Dejager, D. Mills, and A. Schweizer, "Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial," *Diabetes Care*, vol. 30, no. 2, pp. 217–223, 2007.
9. W. D. Strain, V. Lukashevich, W. Kothny, M. J. Hoellinger, and P. M. Paldánus, "Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study," *Lancet*, vol.382, no. 9890, pp. 409-416, 2003.
10. J. E. Foley, M. C. Bunck, D. L. Möller-Goede et al., "Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naïve patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial," *Diabetologia*, vol. 54, no. 8, pp. 1985–1991, 2011.
11. F. X. Pi-Sunyer, A. Schweizer, D. Mills, and S. Dejager, "Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes," *Diabetes Research and Clinical Practice*, vol. 76, no. 1, pp. 132–138, 2007.
12. E. Bosi, F. Dotta, Y. Jia, and M. Goodman, "Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naïve patients with type 2 diabetes mellitus," *Diabetes Obesity and Metabolism*, vol. 11, no. 5, pp. 506–515, 2009.

13. E. Bosi, R. P. Camisasca, C. Collober, E. Rochotte, and A. J. Garber, "Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin," *Diabetes Care*, vol. 30, no. 4, pp. 890–895, 2007.
14. C. Pan, X. Xing, P. Han et al., "Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus," *Diabetes Obesity and Metabolism*, vol. 14, no. 8, pp. 737–744, 2012.
15. E. Ferrannini, V. Fonseca, B. Zinman et al., "Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy," *Diabetes Obesity and Metabolism*, vol. 11, no. 2, pp. 157–166, 2009.
16. C. Filozof and J. F. Gautier, "A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study," *Diabetic Medicine*, vol. 27, no. 3, pp. 318–326, 2010.
17. G. Bolli, F. Dotta, L. Colin, B. Minic, and M. Goodman, "Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin," *Diabetes Obesity and Metabolism*, vol. 11, no. 6, pp. 589–595, 2009.